Pay in 4 interest-free payments of $6.37 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Key Players in the Obesity GLP-1 Market Novo Nordisk Eli Lilly and Company Amgen BoehringerIngelheim AstraZeneca Pfizer Roche Viking Therapeutics Structure Therapeutics Zealand Pharma Scope of the Report Obesity GLP-1 Market by Segments By Molecule Class: Semaglutide Tirzepatide Other GLP-1 Receptor Agonists By Route of Administration: Injectables Oral Formulations By Payer Type: Public Coverage Private Insurance and Self-Pay By Use-Case Framing: Weight Management Cardiovascular Risk Anchored By Region: North America United States Canada Mexico Europe Germany United Kingdom France Italy Spain Netherlands Rest of Europe East Asia China Japan South Korea South Asia and Pacific India Australia New Zealand Frequently Asked Questions How big is the obesity GLP-1 market in 2025
Correct coding is 64488 because the procedure was performed bilaterally by injections
Novo Nordisk Canada patient support Novo Nordisk Canada offers a patient support program that may provide injection training, insurance-navigation help, and in some cases financial assistance for patients with limited coverage
Our team always uses a new, sterile needle and syringe for each injection
US$ 21.24
US$ 22.83
US$ 24.62
US$ 28.34
US$ 26.20
US$ 27.00
US$ 24.17
US$ 27.14
